Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #2813423

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	— EUR	— EUR	58 103 EUR	— EUR	58 103 EUR	— EUR	— EUR	— EUR	— EUR	52 809 EUR	— EUR	—	— EUR	— EUR	— EUR	52 809 EUR	— EUR	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	312,000 EUR	—	—
Adjustments for depreciation and amortisation expense	—	—	—	45 405 EUR	—	—	—	—	—	—	—	—	—	—	—	—	4 596 EUR	—	—
Adjustments for provisions	—	—	—	839,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	4,000 EUR	—	—
Adjustments for unrealised foreign exchange losses (gains)	—	—	—	912,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	1 136 EUR	—	—
Adjustments for share-based payments	—	—	—	4 249 EUR	—	—	—	—	—	—	—	—	—	—	—	—	2 617 EUR	—	—
Adjustments for fair value losses (gains)	—	—	—	1 372 EUR	—	—	—	—	—	—	—	—	—	—	—	—	987,000 EUR	—	—
Other adjustments to reconcile profit (loss)	—	—	—	15,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	1 185 EUR	—	—
Cash flows from (used in) operating activities	—	—	—	19 154 EUR	—	—	—	—	—	—	—	—	—	—	—	—	58 457 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	7,000 EUR	—	—
Purchase of property, plant and equipment, classified as investing activities	—	—	—	535,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	929,000 EUR	—	—
Purchase of intangible assets, classified as investing activities	—	—	—	587,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	401,000 EUR	—	—
Proceeds from sales of other long-term assets, classified as investing activities	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	40,000 EUR	—	—
Purchase of other long-term assets, classified as investing activities	—	—	—	1,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	1,000 EUR	—	—
Interest received, classified as investing activities	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	367,000 EUR	—	—
Cash flows from (used in) investing activities	—	—	—	1 877 EUR	—	—	—	—	—	—	—	—	—	—	—	—	917,000 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	—	—	198,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	499,000 EUR	—	—
Proceeds from borrowings, classified as financing activities	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	28 700 EUR	—	—
Interest paid, classified as financing activities	—	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	312,000 EUR	—	—
Cash flows from (used in) financing activities	—	—	—	1 828 EUR	—	—	—	—	—	—	—	—	—	—	—	—	26 818 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	—	—	428,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	483,000 EUR	—	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	—	—	19 531 EUR	—	—	—	—	—	—	—	—	—	—	—	—	33 037 EUR	—	—
Cash and cash equivalents	84 225 EUR	—	—	—	—	—	—	—	—	—	—	—	103 756 EUR	—	—	—	—	—	136 792 EUR